NDAINTRAVENOUSPOWDERPriority Review
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
CONTEPO (fosfomycin disodium) by Meitheal is [ see microbiology () ] . First approved in 2025.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONTEPO (fosfomycin disodium) is an intravenous antibiotic powder approved in October 2025 for treatment of serious bacterial infections. It works by inhibiting bacterial cell wall synthesis through a unique mechanism distinct from beta-lactams. The drug represents a novel therapeutic option in the IV antibiotic space with potential applications in resistant gram-positive and gram-negative pathogens.
Growth12.3 years to LOE
Early-stage launch with zero reported competitive pressure creates significant opportunity for commercial build-out and team expansion.
Mechanism of Action
[ see Microbiology () ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONTEPO represents a launch-stage opportunity with zero existing linked job postings, indicating early-stage team building and significant hiring potential across commercial and medical functions. Professionals joining now position themselves as foundational team members during the critical market establishment phase of a patented IV antibiotic with no direct competition.
Brand ManagerField Sales Representative
Worked on CONTEPO at Meitheal? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.